Reply from the Authors

To the Editor,
We would like to thank the authors for showing interest in our letter, which was titled "Investigation of MDM2 oncogene copy number alterations in cases of chronic lymphocytic leukemia" [1] . The authors have shown two previously published articles related to overexpression of MDM2 in CLL patients. One of them was written by Watanabe et al. [2] ; they performed Southern blot analysis to examine whether MDM2 was amplified in 23 B-CLL specimens and found that none of the patients showed amplification. In the other study, Bixby et al. [3] reported that they had found three copies of the MDM2 gene in 37 of 178 CLL patients using 50K SNParray technology. After screening the literature in detail, we found two additional studies. Bueso-Ramos et al. [4] reported 5 CLL patients not showing amplification using the Southern blot method and Huang et al. [5] reported 4 of 11 patients with CLL showing amplification of the MDM2 gene using the Southern blot technique. Considering these four studies, amplification of the MDM2 gene
